Cargando…

Metabolic features of cancer cells impact immunosurveillance

BACKGROUND: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upre...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Adrien, Juncheng, Pan, Mondini, Michele, Labaied, Nizar, Loi, Mauro, Adam, Julien, Lafarge, Antoine, Astesana, Valentina, Obrist, Florine, Klein, Christophe, Bloy, Norma, Stoll, Gautier, Signolle, Nicolas, Genestie, Catherine, Damotte, Diane, Alifano, Marco, Leary, Alexandra, Pautier, Patricia, Morice, Philippe, Gouy, Sebastien, Deutsch, Eric, Chargari, Cyrus, Dieu-Nosjean, Marie-Caroline, Cremer, Isabelle, Michels, Judith, Kroemer, Guido, Castedo, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231002/
https://www.ncbi.nlm.nih.gov/pubmed/34162714
http://dx.doi.org/10.1136/jitc-2021-002362
_version_ 1783713334921527296
author Joseph, Adrien
Juncheng, Pan
Mondini, Michele
Labaied, Nizar
Loi, Mauro
Adam, Julien
Lafarge, Antoine
Astesana, Valentina
Obrist, Florine
Klein, Christophe
Bloy, Norma
Stoll, Gautier
Signolle, Nicolas
Genestie, Catherine
Damotte, Diane
Alifano, Marco
Leary, Alexandra
Pautier, Patricia
Morice, Philippe
Gouy, Sebastien
Deutsch, Eric
Chargari, Cyrus
Dieu-Nosjean, Marie-Caroline
Cremer, Isabelle
Michels, Judith
Kroemer, Guido
Castedo, Maria
author_facet Joseph, Adrien
Juncheng, Pan
Mondini, Michele
Labaied, Nizar
Loi, Mauro
Adam, Julien
Lafarge, Antoine
Astesana, Valentina
Obrist, Florine
Klein, Christophe
Bloy, Norma
Stoll, Gautier
Signolle, Nicolas
Genestie, Catherine
Damotte, Diane
Alifano, Marco
Leary, Alexandra
Pautier, Patricia
Morice, Philippe
Gouy, Sebastien
Deutsch, Eric
Chargari, Cyrus
Dieu-Nosjean, Marie-Caroline
Cremer, Isabelle
Michels, Judith
Kroemer, Guido
Castedo, Maria
author_sort Joseph, Adrien
collection PubMed
description BACKGROUND: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types. METHODS: Tumors from patients with locally advanced cervical carcinoma (LACC) and non-small cell lung cancer (NSCLC) were stained for PAR, PDXK, dendritic cell lysosomal associated membrane glycoprotein (DC-LAMP) and CD8 T cell infiltration. Their correlations and prognostic impact were assessed. Cisplatin-resistant NSCLC cell clones isolated from Lewis-lung cancer (LLC) cells were evaluated for PAR levels by immunoblot. Parental (PAR(low)) and cisplatin-resistant (PAR(high)) clones were subcutaneously injected into the flank of C57BL/6 mice. Tumors were harvested to evaluate their immune infiltration by flow cytometry. RESULTS: The infiltration of tumors by CD8 T and DC-LAMP(+) cells was associated with a favorable overall survival in patients with LACC (p=0.006 and p=0.008, respectively) and NSCLC (p<0.001 for both CD8 T and DC-LAMP cells). We observed a positive correlation between PDXK expression and the infiltration by DC-LAMP (R=0.44, p=0.02 in LACC, R=0.14, p=0.057 in NSCLC), and a negative correlation between PAR levels and CD8 T lymphocytes (R=−0.39, p=0.034 in LACC, R=−0.18, p=0.017 in NSCLC). PARP1 is constitutively hyperactivated in cisplatin-resistant LLC cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PAR(high)). Tumors formed by such cancer cells injected into immunocompetent mice were scarcely infiltrated by CD8 T (p=0.028) and antigen presenting cells (p=0.086). CONCLUSIONS: Oncometabolic features can impact local immunosurveillance, providing new functional links between cisplatin resistance and therapeutic failure.
format Online
Article
Text
id pubmed-8231002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82310022021-07-09 Metabolic features of cancer cells impact immunosurveillance Joseph, Adrien Juncheng, Pan Mondini, Michele Labaied, Nizar Loi, Mauro Adam, Julien Lafarge, Antoine Astesana, Valentina Obrist, Florine Klein, Christophe Bloy, Norma Stoll, Gautier Signolle, Nicolas Genestie, Catherine Damotte, Diane Alifano, Marco Leary, Alexandra Pautier, Patricia Morice, Philippe Gouy, Sebastien Deutsch, Eric Chargari, Cyrus Dieu-Nosjean, Marie-Caroline Cremer, Isabelle Michels, Judith Kroemer, Guido Castedo, Maria J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types. METHODS: Tumors from patients with locally advanced cervical carcinoma (LACC) and non-small cell lung cancer (NSCLC) were stained for PAR, PDXK, dendritic cell lysosomal associated membrane glycoprotein (DC-LAMP) and CD8 T cell infiltration. Their correlations and prognostic impact were assessed. Cisplatin-resistant NSCLC cell clones isolated from Lewis-lung cancer (LLC) cells were evaluated for PAR levels by immunoblot. Parental (PAR(low)) and cisplatin-resistant (PAR(high)) clones were subcutaneously injected into the flank of C57BL/6 mice. Tumors were harvested to evaluate their immune infiltration by flow cytometry. RESULTS: The infiltration of tumors by CD8 T and DC-LAMP(+) cells was associated with a favorable overall survival in patients with LACC (p=0.006 and p=0.008, respectively) and NSCLC (p<0.001 for both CD8 T and DC-LAMP cells). We observed a positive correlation between PDXK expression and the infiltration by DC-LAMP (R=0.44, p=0.02 in LACC, R=0.14, p=0.057 in NSCLC), and a negative correlation between PAR levels and CD8 T lymphocytes (R=−0.39, p=0.034 in LACC, R=−0.18, p=0.017 in NSCLC). PARP1 is constitutively hyperactivated in cisplatin-resistant LLC cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PAR(high)). Tumors formed by such cancer cells injected into immunocompetent mice were scarcely infiltrated by CD8 T (p=0.028) and antigen presenting cells (p=0.086). CONCLUSIONS: Oncometabolic features can impact local immunosurveillance, providing new functional links between cisplatin resistance and therapeutic failure. BMJ Publishing Group 2021-06-23 /pmc/articles/PMC8231002/ /pubmed/34162714 http://dx.doi.org/10.1136/jitc-2021-002362 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Immunotherapy Biomarkers
Joseph, Adrien
Juncheng, Pan
Mondini, Michele
Labaied, Nizar
Loi, Mauro
Adam, Julien
Lafarge, Antoine
Astesana, Valentina
Obrist, Florine
Klein, Christophe
Bloy, Norma
Stoll, Gautier
Signolle, Nicolas
Genestie, Catherine
Damotte, Diane
Alifano, Marco
Leary, Alexandra
Pautier, Patricia
Morice, Philippe
Gouy, Sebastien
Deutsch, Eric
Chargari, Cyrus
Dieu-Nosjean, Marie-Caroline
Cremer, Isabelle
Michels, Judith
Kroemer, Guido
Castedo, Maria
Metabolic features of cancer cells impact immunosurveillance
title Metabolic features of cancer cells impact immunosurveillance
title_full Metabolic features of cancer cells impact immunosurveillance
title_fullStr Metabolic features of cancer cells impact immunosurveillance
title_full_unstemmed Metabolic features of cancer cells impact immunosurveillance
title_short Metabolic features of cancer cells impact immunosurveillance
title_sort metabolic features of cancer cells impact immunosurveillance
topic Immunotherapy Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231002/
https://www.ncbi.nlm.nih.gov/pubmed/34162714
http://dx.doi.org/10.1136/jitc-2021-002362
work_keys_str_mv AT josephadrien metabolicfeaturesofcancercellsimpactimmunosurveillance
AT junchengpan metabolicfeaturesofcancercellsimpactimmunosurveillance
AT mondinimichele metabolicfeaturesofcancercellsimpactimmunosurveillance
AT labaiednizar metabolicfeaturesofcancercellsimpactimmunosurveillance
AT loimauro metabolicfeaturesofcancercellsimpactimmunosurveillance
AT adamjulien metabolicfeaturesofcancercellsimpactimmunosurveillance
AT lafargeantoine metabolicfeaturesofcancercellsimpactimmunosurveillance
AT astesanavalentina metabolicfeaturesofcancercellsimpactimmunosurveillance
AT obristflorine metabolicfeaturesofcancercellsimpactimmunosurveillance
AT kleinchristophe metabolicfeaturesofcancercellsimpactimmunosurveillance
AT bloynorma metabolicfeaturesofcancercellsimpactimmunosurveillance
AT stollgautier metabolicfeaturesofcancercellsimpactimmunosurveillance
AT signollenicolas metabolicfeaturesofcancercellsimpactimmunosurveillance
AT genestiecatherine metabolicfeaturesofcancercellsimpactimmunosurveillance
AT damottediane metabolicfeaturesofcancercellsimpactimmunosurveillance
AT alifanomarco metabolicfeaturesofcancercellsimpactimmunosurveillance
AT learyalexandra metabolicfeaturesofcancercellsimpactimmunosurveillance
AT pautierpatricia metabolicfeaturesofcancercellsimpactimmunosurveillance
AT moricephilippe metabolicfeaturesofcancercellsimpactimmunosurveillance
AT gouysebastien metabolicfeaturesofcancercellsimpactimmunosurveillance
AT deutscheric metabolicfeaturesofcancercellsimpactimmunosurveillance
AT chargaricyrus metabolicfeaturesofcancercellsimpactimmunosurveillance
AT dieunosjeanmariecaroline metabolicfeaturesofcancercellsimpactimmunosurveillance
AT cremerisabelle metabolicfeaturesofcancercellsimpactimmunosurveillance
AT michelsjudith metabolicfeaturesofcancercellsimpactimmunosurveillance
AT kroemerguido metabolicfeaturesofcancercellsimpactimmunosurveillance
AT castedomaria metabolicfeaturesofcancercellsimpactimmunosurveillance